GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dicerna Pharmaceuticals Inc (NAS:DRNA) » Definitions » Cost of Goods Sold

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Cost of Goods Sold : $0.0 Mil (TTM As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Dicerna Pharmaceuticals Cost of Goods Sold?

Dicerna Pharmaceuticals's cost of goods sold for the three months ended in Sep. 2021 was $0.0 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Sep. 2021 was $0.0 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Dicerna Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2021 was 100%.

Cost of Goods Sold is also directly linked to Inventory Turnover.


Dicerna Pharmaceuticals Cost of Goods Sold Historical Data

The historical data trend for Dicerna Pharmaceuticals's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dicerna Pharmaceuticals Cost of Goods Sold Chart

Dicerna Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dicerna Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Dicerna Pharmaceuticals Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dicerna Pharmaceuticals  (NAS:DRNA) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Dicerna Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2021 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(62.954 - 0) / 62.954
=100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Dicerna Pharmaceuticals's Inventory Turnover for the three months ended in Sep. 2021 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Dicerna Pharmaceuticals Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Hayden Avenue, Lexington, MA, USA, 02421
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.
Executives
Bob D Brown officer: See Remarks 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Shreeram Aradhye officer: EVP & Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Marc D Kozin director
Douglas Fambrough director, officer: President and CEO C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
James B Weissman officer: Chief Operating Officer & EVP C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Regina M. Paglia officer: Chief Human Resources Officer C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Robert D. Ciappenelli officer: Chief Commercial Officer DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Patrick M. Gray director C/O CIVITAS SOLUTIONS, INC. 313 CONGRESS STREET, 6TH FLOOR BOSTON MA 02210
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Martin I Freed director 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Stephen J Hoffman director C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Headlines

From GuruFocus

Dicerna to Participate in 16th Annual Citi Biopharma Conference

By Business Wire Business Wire 09-02-2021

Dicerna Announces New Executive Leadership Appointments

By Business Wire Business Wire 09-22-2021